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at market entry of each drug of interest and using a sequential propensity score 
matched cohort design. We applied four BRA metrics: number needed to treat and 
number needed to harm (NNT|NNH); incremental net benefit (INB) with maximum 
acceptable risk [MAR], INB with relative-value adjusted life years [RVALYs], and INB 
with quality-adjusted life years [QALYs]. We determined whether and when the 
bootstrapped 99% confidence interval (CI) for each metric excluded zero, indicating 
net favorability of one drug over the other. Results: For rofecoxib, all four metrics 
yielded a negative value, suggesting net favorability of ns-NSAIDs over rofecoxib, 
and the 99% CI for all but the NNT|NNH excluded the null during follow-up. For 
prasugrel, only the 99% CI for INB-QALY excluded the null, but trends in values 
over time were similar across the four metrics, suggesting overall net favorability 
of prasugrel versus clopidogrel. The 99% CI for INB-RVALY and INB-QALY excluded 
the null in the denosumab example, suggesting net favorability of denosumab over 
bisphosphonates. ConClusions: Prospective benefit-risk monitoring can be used 
to determine net favorability of a new drug in electronic healthcare data. In three 
examples, existing BRA metrics produced qualitatively similar results but differed 
with respect to alert generation. INB-QALY produced the most conclusive findings 
across the three examples.
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objeCtives: To evaluate operational definitions for cardiac events related to QT 
prolongation, such as paroxysmal ventricular tachycardia, ventricular fibrillation 
and flutter, cardiac arrest, and sudden cardiac death, in retrospective studies using 
administrative databases. Methods: Using PubMed, we searched for studies that 
retrospectively identified cardiac events related to QT prolongation in administra-
tive or claims databases and were published between January 2000 and September 
2014. Selection for full-text review was based on a preliminary review of titles and 
abstracts. Results: Our initial search yielded 988 articles from which five were 
selected for inclusion after full-text review. Case report, clinical trial, congenital long 
QT syndrome, cardiac event not related to QT prolongation, and electrocardiography 
utilization are reasons for exclusion. Seven additional articles were identified from 
the references of these articles. The twelve included articles consist of four cohort 
studies (33%), three case-control studies (25%), three validation studies (25%), and 
two descriptive studies (17%). Nine studies (75%) utilized databases from the United 
States, five (42%) of which used Medicaid data, and three (25%) used European data. 
The most common operation definitions for cardiac events related to QT prolonga-
tion were primary discharge diagnosis of long QT-related cardiac events (75%) and 
sudden cardiac death (25%). The most common administrative codes utilized were 
ICD-9 (83%) and ICD-10 (17%). The most frequently utilized ICD-9 diagnosis code 
was 427.x (100%, cardiac dysrhythmias, ICD-10: I47-49), followed by 426.x (33%, con-
duction disorders, ICD-10: I44-45), and 798.x (33%, sudden death, cause unknown, 
ICD-10: R96). Six studies (50%) reviewed medical records to validate the diagnosis 
codes. Positive predictive values ranged from 77-94% when defining cardiac events 
related to QT prolongation using ICD-9 codes 426.x or 427.x. ConClusions: In 
administrative databases, ICD-9 codes 426.x and 427.x as the principle discharge 
diagnosis or underlying cause of death are commonly used to identify cardiac events 
related to QT prolongation.
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objeCtives: We compared benefit-risk assessment (BRA) methods for determining 
whether and when sufficient evidence exists to indicate that one drug is favora-
ble over another in prospective monitoring. Methods: We simulated prospective 
monitoring of a new drug (A) versus an alternative (B) with respect to two beneficial 
and three harmful outcomes. We generated data for 1,000 iterations of six sce-
narios and applied four BRA metrics: number needed to treat and number needed 
to harm (NNT|NNH); incremental net benefit (INB) with maximum acceptable risk 
(INB-MAR); INB with relative-value adjusted life years (INB-RVALY); and INB with 
quality-adjusted life years (INB-QALY). We determined the proportion of iterations 
in which the 99% confidence interval (CI) for each metric included and excluded the 
null and we calculated mean time-to-alerting. Results: With no true difference 
in any outcome between drugs A and B, the proportion of iterations including the 
null was lowest for INB-RVALY (64%) and highest for INB-QALY (76%). When drug 
A was more effective and the drugs were equally safe, INB-QALY indicated net 
favorability of drug A in 81% of iterations, INB-MAR and INB-RVALY indicated net 
favorability in 79% of iterations, and NNT|NNH indicated net favorability in 72% of 
iterations. When drug A was safer than drug B, NNT|NNH had the highest proportion 
of iterations indicating net favorability of drug A (65%). Mean time-to-alerting was 
similar among methods across the six scenarios. ConClusions: BRA metrics can 
be useful for identifying net favorability when applied to prospective monitoring 
of a new drug versus an alternative. INB-based approaches similarly outperform 
unweighted NNT|NNH approaches.
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objeCtives: It is essential to reduce potential bias by adjusting for confounders 
when performing real world data analysis. It is informative to investigate usage of 
ent to materially affect ICERs. More conservatively, assuming no treatment effect 
beyond 10-years still resulted in 0.35 life years gained, a significant gain compared to 
the 10-year horizon. Varying assumptions in different ways altered the magnitudes 
of the gains in LYs (and potentially cost-effectiveness), but not the essential conclu-
sions. ConClusions: This research confirms Gray’s suggestion of the importance 
of extending analysis time horizons when differential mortality is observed at the 
end of a study. Under any reasonable assumption applied to the extrapolation, any 
survival difference at end of study must persist to some degree beyond that time 
and therefore add to the treatment benefit observed up to the point of extrapola-
tion. Ignoring the post-study period biases clinical and cost-effectiveness results.
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objeCtives: Comorbidity scores are frequently used for controlling confounding in 
observational studies using administrative claims. Several comorbidity measures 
have been developed and evaluated for predicting a variety of outcomes. However, 
scores are often used with outcomes other than those included in validation studies. 
Few publications have compared the performance of different scores in predicting 
different types of outcomes. The objective of the present study was to compare the 
Charlson Comorbidity Index (CCI), a frequently used diagnosis-based comorbidity 
score, and Rx Risk, a prescription-based comorbidity score, as predictors of three 
outpatient outcomes. Methods: A retrospective analysis was conducted using 
Mississippi Medicaid medical and pharmacy claims data for the period January 2010 
to December 2011. Inclusion criteria were continuous enrolment during the observa-
tion period, not dual-eligible, and having both medical and pharmacy claims in both 
calendar years. CCI scores and Rx Risk Scores were calculated using 2010 claims. 
Scores were evaluated as predictors of outpatient visits, total outpatient costs and 
total pharmacy costs in 2011. Costs were log transformed. A base general linear 
model with age, gender, race and ethnicity was developed. Predictive ability of each 
comorbidity score was measured as the change in R2 when the score was added 
to the base model. Results: R2s for the base model were visits - 0.07, outpatient 
costs - 0.01, and pharmacy costs - 0.03. CCI and Rx Risk improved prediction for visits 
and pharmacy costs (CCI R2s; 0.10, 0.05; Rx Risk R2s; 0.13, 0.07). ConClusions: 
Although CCI is often used for outpatient outcomes, Rx Risk provides a better 
measure of comorbidity when the dependent variables are outpatient utilization or 
costs. The CCI was developed for predicting mortality during hospitalization. These 
results indicate that comorbidity scores developed for predicting outpatient out-
comes would be better for controlling for comorbidity in outpatient based studies.
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objeCtives: Indirect treatment comparisons (ITCs) are an important part of any 
comparative effective demonstration in the absence of head-to-head clinical trials. 
Classic ITCs can lead to biased results due to differences in patient populations and 
trial designs. These differences can be corrected for by using matching-adjusted ITC 
(MAIC) technique. Furthermore, extrapolation of survival data beyond clinical trial 
results may be required for economic evaluations. The objective of this research was 
to compare lenvatinib and sorafenib in patients with RAI-Refractory DTC using MAIC 
and survival extrapolation techniques. Methods: Mean overall survival (OS) and 
progression-free survival (PFS) outcomes were estimated by weighting lenvatinib’s 
patient level data based on baseline characteristics from sorafenib phase 3 trial 
using logistic regression. Classic ITC was performed before and after adjustment. 
Extrapolation of OS and PFS was performed using proportional hazard, acceler-
ated time failure, individual parametric models and piecewise models (Royston 
& Parmar). Results were presented as hazard ratios (HR) with confidence intervals 
(CI). Results: Unadjusted ITCs for Lenvatinib vs. placebo were 0.746(0.497; 1.119) 
for OS and 0.213(0.158; 0.288) for PFS. The MAIC provided statistically significant 
estimates of 0.577 (0.347; 0.959) for OS and 0.170(0.118; 0.254) for PFS vs. placebo. 
Unadjusted ITCs vs. sorafenib were 0.933(0.529; 1.643) and 0.362(0.245; 0.536) respec-
tively for OS and PFS; while MAIC results were 0.721(0.379; 1.373) and 0.325(0.201; 
0.526) respectively for OS and PFS. Survival extrapolation provided estimates of 7.5-
10 month of additional OS gain for Lenvatinib vs. placebo, with the MAIC extrapola-
tion showing the largest gain and a good model fit. ConClusions: This analysis 
demonstrated that in absence of head-to-head trials, MITC offers important meth-
odology to adjust for population and trial differences, especially in orphan diseases 
where limited data are available. MAIC can increase the reliability of comparative 
effectiveness data and support payers decision making.
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objeCtives: Benefit-risk assessment (BRA) methods can combine measures of 
benefits and risks into a single value. We examined BRA metrics for prospective 
monitoring of new drugs in electronic healthcare data. Methods: Using two 
databases, we emulated prospective monitoring of three drugs versus compara-
tors (rofecoxib vs. non-selective non-steroidal anti-inflammatory drugs [ns-NSAIDs], 
prasugrel versus clopidogrel, and denosumab versus bisphosphonates) beginning 
